Search NLS News

A recent government investigation proposes the establishment of three new funding agencies in Sweden, The Science Agency, The Strategic Research Agency and The Innovation Agency. At the same time, the current funding agencies, Formas, Forte, the Swedish Research Council, and Vinnova, are phased out, and the funding of research and innovation at the Swedish Energy […]

The Board of Directors of the company has appointed Christine Lind as new Chief Executive Officer. “We are delighted to welcome Christine Lind to Bactiguard. With her extensive expertise in life sciences, coupled with international, strategic, and commercial skills, she brings valuable insights to us. As Bactiguard has embraced a sharpened license focused strategy, the […]

Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed. “The treatment has the potential to become a very important alternative for those patients whose disease no longer respond to standard […]

The company plans to restructure and reduce its workforce by 20-25%, with expected annual costs savings of SEK 20 million. “Over the last 12 months our OPTIMIZE-1 trial evaluating our lead asset mitazalimab in pancreatic cancer has delivered two sets of highly encouraging interim data as well as faster-than-expected patient recruitment leading to an accelerated […]

In connection with the company’s decision to develop a nasal vaccine candidate for influenza, based on recent progress with its mucosal vaccine platform, the board of Abera has decided to conduct a directed new share issue. Abera’s platform enables mucosal immunization, such as through nasal spray, which can inhibit the growth of viruses and bacteria […]

Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at USD 16.5 billion on an enterprise value basis. Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire all outstanding shares of CDMO Catalent for USD 63.50 per share […]

Innovate UK, the UK’s innovation agency, has taken a group of eleven UK businesses specializing in advanced therapy medicinal products (ATMP) for a deep dive into the Swedish ecosystem. During visits to institutions like Karolinska Institutet, the KTH Royal Institute and AstraZeneca, the UK delegation got a chance to forge new collaboration partnerships with the […]

The two biologics Contract Development and Manufacturing Organizations (CDMOs), have announced their combination. Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P extends the group’s value proposition to address complex customer needs across the entire development cycle, the companies state. Keensight Capital will continue to help the Group strengthen its position […]

In June 2023 Ashfield Nordics became Inizio Engage Nordic. A purpose-built brand, set to change the way the industry interacts with its customers, Inizio Engage now combines the strength, expertise, and proven track record of Ashfield Engage and The Creative Engagement Group into a unified global strategic, commercial, and creative engagement partner. Inizio Engage was […]

Orion Corporation and Newel Health have entered into a license agreement regarding ODD-403, a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialize ODD-403. Orion is […]